Intra-amniotic Administration of Proteins for the Treatment of Ectodermal Dysplasias

Simple SummaryContent extracted from patent full text and abstract with AI.

The patent discloses a method for treating ectodermal dysplasias, specifically X-linked hypohidrotic ectodermal dysplasia (XLHED), by administering therapeutic proteins such as EDI200 directly into the amniotic fluid of a developing fetus. This intra-amniotic treatment aims to correct or ameliorate abnormalities in the development of ectodermal structures (e.g., hair, teeth, sweat glands) associated with these genetic disorders. EDI200 is a recombinant, humanized fusion protein designed to activate necessary signaling pathways for normal ectodermal development.

Use CasesContent extracted from patent full text and abstract with AI.

• Prenatal treatment of fetuses diagnosed or suspected to have XLHED to restore normal development of ectodermal tissues.
• Improvement of outcomes in other forms of ectodermal dysplasias where prenatal intervention is possible and beneficial.
• Potential adaptation for gene or protein therapy protocols where direct fetal delivery is beneficial for congenital disorders involving disrupted protein signaling.
• Refinement of targeted drug delivery methods in utero for various developmental disorders by leveraging immune-privileged amniotic environments.

BenefitsContent extracted from patent full text and abstract with AI.

• Direct intra-amniotic administration allows targeted delivery of the therapeutic protein to the fetus, improving efficacy.
• Reduces exposure of the mother to the therapeutic agent, minimizing maternal side effects.
• Significantly improves or restores normal phenotype in affected fetuses (hair, teeth, sweat glands, etc.), as shown in animal models.
• May offer a one-time prenatal intervention with long-lasting positive effects.
• Avoids inducing immune responses due to the immune-privileged status of the amniotic fluid.
• Fills an unmet clinical need for effective prenatal therapies for ectodermal dysplasias, potentially improving quality of life and reducing postnatal morbidity and mortality.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The disclosure relates to methods for the intra-amniotic administration of ectodysplasin A (EDA) agonists, in particular EDI200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, X-linked hypohidrotic ectodermal dysplasia (XLHED).